BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24497999)

  • 41. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
    Schuhmacher C; Gretschel S; Lordick F; Reichardt P; Hohenberger W; Eisenberger CF; Haag C; Mauer ME; Hasan B; Welch J; Ott K; Hoelscher A; Schneider PM; Bechstein W; Wilke H; Lutz MP; Nordlinger B; Van Cutsem E; Siewert JR; Schlag PM
    J Clin Oncol; 2010 Dec; 28(35):5210-8. PubMed ID: 21060024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
    BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis.
    Jiang L; Yang KH; Guan QL; Chen Y; Zhao P; Tian JH
    J Clin Gastroenterol; 2015; 49(5):387-94. PubMed ID: 25144898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
    Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.
    Malthaner RA; Wong RK; Rumble RB; Zuraw L;
    BMC Med; 2004 Sep; 2():35. PubMed ID: 15447788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.
    Rydzewska L; Tierney J; Vale CL; Symonds PR
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD007406. PubMed ID: 23235641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapy in gastric cancer. From an oncological perspective].
    Wilke H; Stahl M
    Chirurg; 2009 Nov; 80(11):1023-7. PubMed ID: 19902288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials.
    Fu T; Bu ZD; Li ZY; Zhang LH; Wu XJ; Wu AW; Shan F; Ji X; Dong QS; Ji JF
    BMC Cancer; 2015 Apr; 15():322. PubMed ID: 25928286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proximal Gastric Resection with Posterior Esophago-Gastrostomy and Partial Neo-Fundoplication in the Treatment of Advanced Upper Gastric Carcinoma.
    Polkowski WP; Mielko J; Gęca K; Rawicz-Pruszyński K; Ciseł B; Kurylcio A; Skórzewska M
    Dig Surg; 2020; 37(2):119-128. PubMed ID: 30909273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 52. Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis.
    Luo H; Wu L; Huang M; Jin Q; Qin Y; Chen J
    Medicine (Baltimore); 2018 Oct; 97(43):e12932. PubMed ID: 30412102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature.
    Cho H; Nakamura J; Asaumi Y; Yabusaki H; Sakon M; Takasu N; Kobayashi T; Aoki T; Shiraishi O; Kishimoto H; Nunobe S; Yanagisawa S; Suda T; Ueshima S; Matono S; Maruyama H; Tatsumi M; Seya T; Tanizawa Y; Yoshikawa T
    Ann Surg Oncol; 2015 Mar; 22(3):787-92. PubMed ID: 25223927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
    Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
    Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials.
    Coccolini F; Cotte E; Glehen O; Lotti M; Poiasina E; Catena F; Yonemura Y; Ansaloni L
    Eur J Surg Oncol; 2014 Jan; 40(1):12-26. PubMed ID: 24290371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
    Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
    Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials.
    Mocellin S; Nitti D
    Cancer Treat Rev; 2015 May; 41(5):448-54. PubMed ID: 25814393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis.
    Chen Y; Shi XE; Tian JH; Yang XJ; Wang YF; Yang KH
    Medicine (Baltimore); 2018 May; 97(20):e10634. PubMed ID: 29768327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
    Hosoda K; Azuma M; Katada C; Moriya H; Mieno H; Ishido K; Ema A; Ushiku H; Wada T; Washio M; Watanabe A; Higuchi K; Tanabe S; Koizumi W; Watanabe M; Yamashita K
    Gastric Cancer; 2019 May; 22(3):598-606. PubMed ID: 30284080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.